Some startups talk about changing the world, others put their money where the molecules are. AltrixBio just closed a $5M Series A, and this isn’t just another biotech headline, it’s the first step in taking a scalpel-free shot at Type 2 diabetes, obesity, and fatty liver disease. Founded in 2019, the company was born out of Brigham and Women’s Hospital and Harvard Medical School when Dr. Jeff Karp and Dr. Ali Tavakkoli noticed something wild: bariatric patients were seeing Type 2 diabetes fade before the pounds did. That insight became AltrixBio’s DNA, mimic the metabolic miracle of surgery without the knife.
Headquartered in Lowell with research roots in Cambridge, AltrixBio is advancing LuCI, Luminal Coating of the Intestine, as its flagship program, AJN 003. Think of it as “Surgery in a Pill.” A once-daily capsule coats the gut to trigger the same metabolic signals as bypass surgery. The mechanism is clean, the safety profile is rooted in decades of data on sucralfate, and the IP is locked down with US Patent 11,433,094. Instead of chasing another GLP-1 bandwagon, AltrixBio is cutting a new lane: transiently altering nutrient sensing and hormone release to rewire metabolism from the inside out.
The Series A proceeds will fuel AJN 003’s entry into first-in-human clinical trials. AltrixBio has already cleared a critical Pre-IND meeting with the FDA, aligning on clinical, regulatory, and CMC pathways. Translation: this isn’t a moonshot on a cocktail napkin; the company has mapped the regulatory road and secured the patent shield to defend it. That’s why even a $5 million raise matters, when the plan is precise, lean capital can move mountains.
Leadership moves sharpen the story. Nancy Briefs, serial entrepreneur and co-founder, shifts from President and CEO to Executive Chair of the Board. Taking the wheel is David Pass, PharmD, stepping in as President and Chief Executive Officer. With over twenty years across pharma and biotech, including Glooko and Eli Lilly, David Pass has the track record of scaling diabetes and metabolic programs from concept to commercial reality. Paired with the scientific drive of Dr. Jeff Karp and Dr. Ali Tavakkoli, AltrixBio’s leadership is a blend of entrepreneurial fire, clinical authority, and operational muscle.
The market they’re chasing is enormous. Cardiometabolic disease weighed in at $192.9 billion in 2024 and is on pace to hit $305.1 billion by 2032. Type 2 diabetes alone eats up about a third of that. Surgery works but doesn’t scale. Pills do. That’s the void AltrixBio is filling, and if LuCI delivers, it’s more than a therapy, it’s a category shift. $5 million may look modest on paper, but the ambition behind it is anything but.
